DAA-based treatment for HIV-HCV-coinfected patients: analysis of factors of sustained virological response in a real-life study.

IF 1.3 4区 医学 Q4 INFECTIOUS DISEASES
Antiviral Therapy Pub Date : 2020-01-01 DOI:10.3851/IMP3353
Loredana Alessio, Lorenzo Onorato, Vincenzo Sangiovanni, Francesco Borrelli, Elio Manzillo, Vincenzo Esposito, Filomena Simeone, Salvatore Martini, Nicolina Capoluongo, Sebastiano Leone, Giovanni Di Filippo, Maurizio D'Abbraccio, Lucia Aprea, Angelo Salomone Megna, Eugenio Milano, Viviana Rizzo, Annalisa Saracino, Nicola Coppola
{"title":"DAA-based treatment for HIV-HCV-coinfected patients: analysis of factors of sustained virological response in a real-life study.","authors":"Loredana Alessio,&nbsp;Lorenzo Onorato,&nbsp;Vincenzo Sangiovanni,&nbsp;Francesco Borrelli,&nbsp;Elio Manzillo,&nbsp;Vincenzo Esposito,&nbsp;Filomena Simeone,&nbsp;Salvatore Martini,&nbsp;Nicolina Capoluongo,&nbsp;Sebastiano Leone,&nbsp;Giovanni Di Filippo,&nbsp;Maurizio D'Abbraccio,&nbsp;Lucia Aprea,&nbsp;Angelo Salomone Megna,&nbsp;Eugenio Milano,&nbsp;Viviana Rizzo,&nbsp;Annalisa Saracino,&nbsp;Nicola Coppola","doi":"10.3851/IMP3353","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The aim of the present study was to evaluate in HIV-infected patients treated with a direct-acting antiviral agent (DAA)-based regimen the variables associated with sustained virological response (SVR) and the trend in biochemical parameters and clinical events during and after DAA regimen.</p><p><strong>Methods: </strong>We performed a multicentre retrospective cohort study, enrolling all 243 HIV-HCV-coinfected adult patients treated with DAAs between January 2015 and December 2018 in one of the nine participating Infectious Disease Centers in southern Italy, eight in Campania and one in Apulia.</p><p><strong>Results: </strong>Of the 243 patients enrolled, 233 (95.9%) obtained an SVR at 12 weeks (SVR12). Of the 10 patients with non-SVR, 7 were tested for NS3, NS5A and NS5B resistance-associated substitutions (RASs) by sequencing analysis and 6 showed at least 1 major RAS in 1 HCV region (all in NS5A, 2 in NS5B and 1 in NS3). Comparing the 233 patients achieving SVR and the 10 non-achievers, no variable was independently associated with non-SVR. During and after DAA regimen, no modification in the biochemical parameters and clinical events was observed; however, the serum cholesterol and low-density lipoprotein (LDL) levels showed an increase (from 159 ±41.3 mg/dl at baseline to 174 ±44.5 mg/dl at week 12 after stopping treatment, P<0.001, and from 92 ±34.6 mg/dl to 109.4 ±73.7 mg/dl, P=0.002, respectively).</p><p><strong>Conclusions: </strong>The treatment with DAAs led to a high SVR12 rate in HIV-HCV-coinfected subjects, irrespective of epidemiological, clinical or virological characteristics. However, the DAA regimen was associated with an increase in total- and LDL-cholesterol, to be taken into account in the management of HIV infection.</p>","PeriodicalId":8364,"journal":{"name":"Antiviral Therapy","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antiviral Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3851/IMP3353","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 3

Abstract

Background: The aim of the present study was to evaluate in HIV-infected patients treated with a direct-acting antiviral agent (DAA)-based regimen the variables associated with sustained virological response (SVR) and the trend in biochemical parameters and clinical events during and after DAA regimen.

Methods: We performed a multicentre retrospective cohort study, enrolling all 243 HIV-HCV-coinfected adult patients treated with DAAs between January 2015 and December 2018 in one of the nine participating Infectious Disease Centers in southern Italy, eight in Campania and one in Apulia.

Results: Of the 243 patients enrolled, 233 (95.9%) obtained an SVR at 12 weeks (SVR12). Of the 10 patients with non-SVR, 7 were tested for NS3, NS5A and NS5B resistance-associated substitutions (RASs) by sequencing analysis and 6 showed at least 1 major RAS in 1 HCV region (all in NS5A, 2 in NS5B and 1 in NS3). Comparing the 233 patients achieving SVR and the 10 non-achievers, no variable was independently associated with non-SVR. During and after DAA regimen, no modification in the biochemical parameters and clinical events was observed; however, the serum cholesterol and low-density lipoprotein (LDL) levels showed an increase (from 159 ±41.3 mg/dl at baseline to 174 ±44.5 mg/dl at week 12 after stopping treatment, P<0.001, and from 92 ±34.6 mg/dl to 109.4 ±73.7 mg/dl, P=0.002, respectively).

Conclusions: The treatment with DAAs led to a high SVR12 rate in HIV-HCV-coinfected subjects, irrespective of epidemiological, clinical or virological characteristics. However, the DAA regimen was associated with an increase in total- and LDL-cholesterol, to be taken into account in the management of HIV infection.

基于daa的hiv - hcv合并感染患者治疗:现实生活研究中持续病毒学反应因素分析
背景:本研究的目的是评估在接受直接作用抗病毒药物(DAA)治疗的hiv感染患者中与持续病毒学反应(SVR)相关的变量以及DAA治疗期间和之后生化参数和临床事件的趋势。方法:我们进行了一项多中心回顾性队列研究,纳入了2015年1月至2018年12月期间在意大利南部9个参与传染病中心之一(8个在坎帕尼亚,1个在普利亚)接受DAAs治疗的所有243例hiv - hcv合并感染的成年患者。结果:在纳入的243例患者中,233例(95.9%)在12周时获得SVR (SVR12)。在10例非svr患者中,通过测序分析检测了7例NS3、NS5A和NS5B耐药相关替代(RAS),其中6例在1个HCV区域显示至少1个主要RAS(全部在NS5A, 2例在NS5B, 1例在NS3)。233例达到SVR的患者与10例未达到SVR的患者比较,没有变量与非SVR独立相关。在DAA方案期间和之后,未观察到生化参数和临床事件的改变;然而,血清胆固醇和低密度脂蛋白(LDL)水平显示上升(从基线时的159±41.3 mg/dl到停止治疗后的第12周时的174±44.5 mg/dl)。结论:与流行病学、临床或病毒学特征无关,DAAs治疗导致hiv - hcv合并感染受试者的高SVR12发生率。然而,DAA方案与总胆固醇和低密度脂蛋白胆固醇的增加有关,这在HIV感染的管理中需要考虑。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Antiviral Therapy
Antiviral Therapy 医学-病毒学
CiteScore
2.60
自引率
8.30%
发文量
35
审稿时长
4-8 weeks
期刊介绍: Antiviral Therapy (an official publication of the International Society of Antiviral Research) is an international, peer-reviewed journal devoted to publishing articles on the clinical development and use of antiviral agents and vaccines, and the treatment of all viral diseases. Antiviral Therapy is one of the leading journals in virology and infectious diseases. The journal is comprehensive, and publishes articles concerning all clinical aspects of antiviral therapy. It features editorials, original research papers, specially commissioned review articles, letters and book reviews. The journal is aimed at physicians and specialists interested in clinical and basic research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信